Daiwa Securities Group Inc. trimmed its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 53.9% during the first quarter, HoldingsChannel reports. The firm owned 35,383 shares of the company’s stock after selling 41,410 shares during the period. Daiwa Securities Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $555,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Northstar Group Inc. raised its stake in Teva Pharmaceutical Industries by 34.9% during the 4th quarter. Northstar Group Inc. now owns 15,468 shares of the company’s stock worth $239,000 after acquiring an additional 4,000 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in Teva Pharmaceutical Industries by 3.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 49,181 shares of the company’s stock worth $758,000 after acquiring an additional 1,681 shares in the last quarter. AGF Investments America Inc. raised its stake in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. AGF Investments America Inc. now owns 60,321 shares of the company’s stock worth $930,000 after acquiring an additional 1,458 shares in the last quarter. Boston Advisors LLC raised its stake in Teva Pharmaceutical Industries by 18.0% during the 4th quarter. Boston Advisors LLC now owns 23,555 shares of the company’s stock worth $363,000 after acquiring an additional 3,592 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its stake in Teva Pharmaceutical Industries by 420.3% during the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock worth $80,000 after acquiring an additional 4,476 shares in the last quarter. Institutional investors and hedge funds own 67.13% of the company’s stock.
A number of research analysts have commented on TEVA shares. UBS Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research note on Wednesday, January 23rd. Bank of America restated a “buy” rating and issued a $24.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, February 5th. Citigroup dropped their price objective on shares of Teva Pharmaceutical Industries from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, April 11th. Morgan Stanley lowered shares of Teva Pharmaceutical Industries from an “overweight” rating to an “equal weight” rating and set a $17.00 price objective on the stock. in a research note on Wednesday, March 6th. Finally, Credit Suisse Group restated a “hold” rating and issued a $26.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, February 5th. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus price target of $20.58.
In other news, VP Notaristefani Carlo De sold 5,041 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $17.88, for a total value of $90,133.08. Following the sale, the vice president now owns 17,162 shares of the company’s stock, valued at $306,856.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Richard Daniell sold 2,098 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $35,414.24. Following the completion of the sale, the vice president now directly owns 2,098 shares in the company, valued at approximately $35,414.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,691 shares of company stock worth $283,458. Insiders own 0.49% of the company’s stock.
Shares of NYSE:TEVA opened at $14.89 on Tuesday. The stock has a market capitalization of $15.44 billion, a PE ratio of 5.32, a PEG ratio of 2.91 and a beta of 1.30. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 1.69. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $14.04 and a fifty-two week high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.02. The business had revenue of $4.30 billion for the quarter, compared to the consensus estimate of $4.38 billion. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.90%. The business’s quarterly revenue was down 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.94 earnings per share. On average, equities analysts predict that Teva Pharmaceutical Industries Ltd will post 2.3 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2019/05/07/daiwa-securities-group-inc-has-555000-stake-in-teva-pharmaceutical-industries-ltd-teva.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.